

From Static Monographs to Dynamic Phenotyping

The Evolution of Precision Dosing Support

Laura Behm, Pharm.D., BCPS
November 2025

EXECUTIVE SUMMARY

For half a century, the fundamental unit of drug information has been the monograph—a static, consolidated document designed to summarize how a medication interacts with the “average” patient. While this model served the profession well in the era of paper and early digitization, it is increasingly insufficient for the complexity of modern pharmacotherapy. In the intensive care unit, the oncology ward, and the transplant service, there are no average patients. Fluid shifts, organ dysfunction, genetic polymorphisms, and polypharmacy create a dynamic physiological landscape that static text cannot capture.

This white paper outlines a strategic pivot for clinical decision support: the transition from Static Information to Dynamic Pharmacointelligence. By integrating real-time patient data with advanced computational models—specifically Model-Informed Precision Dosing (MIPD) and Digital Twins—we can transform the drug monograph from a passive reference document into an active computational engine. This evolution empowers pharmacists to move beyond population-based “best guesses” to deliver patient-specific precision, driving measurable improvements in safety, length of stay, and cost containment.

1. A FAILURE IN PRECISION: COMPROMISING PATIENT OUTCOMES AND DRIVING UP COSTS

Current drug information resources are built on a fundamental limitation: they rely on population pharmacokinetics. A standard monograph provides a dosing range derived from pre-market clinical trials, which often exclude the very patients clinicians struggle to treat—the elderly, the obese, and those with multi-organ failure.

To apply this to a septic 70-year-old with fluctuating creatinine and significant third-spacing of fluids, the pharmacist must perform a series of complex mental adjustments. This manual “clinical judgment” is prone to variability and error, often resulting in dosing that is either:

- **Sub-therapeutic:** leading to treatment failure and an ineffective patient outcome.
- **Supra-therapeutic:** leading to adverse events and further patient harm.

The primary issue is the failure of this “one-size-fits-all” approach to deliver the best possible outcome for the individual patient. The resulting sub-optimal treatment is not only medically unsound but also cost-ineffective.

The consequences of this reactive, trial-and-error model are costly and economically unsustainable:

- In vancomycin dosing alone, the failure to hit therapeutic targets quickly—a direct consequence of imprecise initial dosing—can extend hospital stays and significantly increase the risk of acute kidney injury (AKI).
- The status quo relies on “trial and error”—administering a standard dose, waiting for a trough level, and reacting to the result.
- In an era of value-based care, where hospitals are penalized for complications and extended lengths of stay, the costs associated with prolonged recovery, treatment failure, and avoidable adverse events make this reactive model economically unsustainable.

2. THE INNOVATION: COMPUTABLE KNOWLEDGE AND BAYESIAN FORECASTING

The solution lies in shifting our product philosophy from retrieving text to computing answers. The technology enabling this shift is Model-Informed Precision Dosing (MIPD), powered by Bayesian data assimilation. Unlike a static calculator that uses a single equation (like Cockcroft-Gault), a Bayesian engine begins with a “prior”—a probability distribution of how a drug behaves in thousands of similar patients. As soon as it ingests data from the specific patient—such as a single drug level or a changing creatinine trend—it updates the model to create a “posterior” probability unique to that individual.

The clinical and economic impact of this approach is validated by real-world data. InsightRX, a leader in this space, demonstrated the power of Bayesian forecasting at OSF Healthcare. By implementing their precision dosing platform, the health system achieved a 50% reduction in severe acute kidney injury (AKI) events and reduced the average length of stay by 1,428 patient days annually. This translated to a total annualized cost reduction of \$3.6 million. Similarly, DoseMeRx has integrated its Bayesian capabilities directly into surveillance workflows with partners like Inovalon, streamlining the process so that precision dosing is not an extra step, but a seamless part of the pharmacist’s daily review. These examples prove that precision dosing is not just a scientific luxury; it is a scalable operational strategy with a hard ROI.

3. THE FRONTIER: PHARMACOKINETIC DIGITAL TWINS

We are rapidly approaching a horizon where the static monograph is replaced by the Pharmacokinetic Digital Twin. A Digital Twin is a virtual replica of a patient’s physiology that allows clinicians to simulate treatments in silico before administering them in real life. This technology is already maturing in metabolic health; Twin Health utilizes “Whole-Body Digital Twins” synthesized from thousands of data points (continuous glucose monitors, activity, sleep) to guide precision nutrition and deprescribing. In randomized trials, this approach led to a >90% reversal of Type 2 Diabetes, allowing patients to eliminate insulin and other medications entirely.

In oncology, the stakes are even higher. Researchers at the National University of Singapore have developed CURATE.AI, an artificial intelligence platform that creates personalized digital twins to optimize chemotherapy dosing. Unlike traditional protocols that push dosing to the “Maximum Tolerated Dose,”

CURATE.AI uses small datasets from the individual patient to identify lower, dynamically adjusted doses that maintain efficacy while significantly reducing toxicity. This “Small Data” approach challenges the Big Data paradigm, proving that for the individual patient, the most valuable dataset is their own.

4. CONCLUSION: THE PHARMACIST AS PRECISION ARCHITECT

The transition from static monographs to dynamic phenotyping represents the maturation of the pharmacy profession. It moves the pharmacist from the role of a “library curator,” checking orders against a rulebook, to that of a Precision Architect, designing therapy using advanced computational tools.

For health technology leaders, the mandate is clear: we must stop digitizing paper processes and start building computable knowledge. The tools to prevent acute kidney injury, reduce length of stay, and optimize chemotherapy already exist. Our challenge is to integrate them into the clinical workflow so seamlessly that the “average” dose becomes a relic of the past, replaced by the precise dose required for the patient right in front of us.

REFERENCES

- InsightRX Case Study: Multi-Health System. InsightRX. Available at: <https://www.insight-rx.com/success-stories/multi-health-sytem-case-study>. Accessed October 2025.
- Inovalon Collaborates with DoseMe to Bring Precision Dosing into Pharmacy Surveillance Workflows. Inovalon News Release. October 14, 2025.
- CURATE.AI: How Digital Twins Are Revolutionizing Precision Dosing. Bio-IT World. May 22, 2025.
- Twin Health and Peloton Partner to Transform Metabolic Health. Twin Health News. Available at: <https://usa.twinhealth.com/company>. Accessed October 2025.
- Whole Body Digital Twin (WBDT) Enabled Diabetes Reversal—US Real-World Findings. Diabetes. 2024 Jun 14;73(Supplement_1).
- Forecasting the impact of artificial intelligence on clinical pharmacy practice. J Am Coll Clin Pharm. 2025;1–9.